These results highlight the potential of combining VEN with FLT3 inhibitors to improve outcomes in FLT3-mutated AML and beyond, with ongoing or completed trials of gilteritinib (NCT05520567, NCT06317649, and NCT06696183) and quizartinib (NCT03735875, NCT03661307, and NCT04687761) eagerly awaiting updated results. The gene discussed is FLT3; the disease is acute myeloid leukemia.